In the Claims:

Please amend the claims as follows:

Claim 1 (currently amended). An adenoviral vector comprising an E2F responsive transcriptional nucleotide regulatory site that controls the expression of an early adenoviral gene, and which adenoviral vector further comprises multiple adenoviral packaging sequences present in adenoviral vectors R1, R2 or R3 ~~that differ in the number of adenoviral packaging sequences, or position of said adenoviral packaging sequences when compared to Onyx 411~~.

Claims 2 – 29 - Canceled.

Claim 30 (previously presented). An adenoviral vector as described in claim 1, wherein said adenoviral vector is of the R1 form.

Claim 31 (previously presented). An adenoviral vector as described in claim 1, wherein said adenoviral vector is of the R2 form.

Claim 32 (previously presented). An adenoviral vector as described in claim 1, wherein said adenoviral vector is of the R3 form.

Claim 33 (previously presented). A method for killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 1.

Claims 34 – 35 - Canceled.

Claim 36 (previously presented). A method for killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 30.

Claim 37 (previously presented). A method of killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 31.

Claim 38 (previously presented). A method of killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 32.

Claim 39 (currently amended). A method of making an adenoviral vector selected from the group consisting of R1, R2 or R3, comprising the steps of infecting cells with ~~said~~ an adenoviral vector having the properties of Onyx 411, said properties comprising two E2F responsive transcriptional nucleotide regulatory sites, and allowing time for said adenoviral vector having the properties of Onyx 411 to replicate in said cells, then isolating from said cells said adenoviral vectors R1, R2, or R3.

Claim 40 - 41 – Withdrawn.

PENDING CLAIMS AFTER INSTANT AMENDMENT

Claim 1. An adenoviral vector comprising an E2F responsive transcriptional nucleotide regulatory site that controls the expression of an early adenoviral gene, and which adenoviral vector further comprises multiple adenoviral packaging sequences present in adenoviral vectors R1, R2 or R3.

Claims 2 – 29 - Canceled.

Claim 30. An adenoviral vector as described in claim 1, wherein said adenoviral vector is of the R1 form.

Claim 31. An adenoviral vector as described in claim 1, wherein said adenoviral vector is of the R2 form.

Claim 32. An adenoviral vector as described in claim 1, wherein said adenoviral vector is of the R3 form.

Claim 33. A method for killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 1.

Claims 34 – 35 - Canceled

Claim 36. A method for killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 30.

Claim 37. A method of killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 31.

Claim 38. A method of killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 32.

Claim 39. A method of making an adenoviral vector selected from the group consisting of R1, R2 or R3, comprising the steps of infecting cells with an adenoviral vector having the properties of Onyx 411, said properties comprising two E2F responsive transcriptional nucleotide regulatory sites, and allowing time for said adenoviral vector having the properties of Onyx 411 to replicate in said cells, then isolating from said cells said adenoviral vectors R1, R2, or R3.

Claim 40 - 41 – Withdrawn